Semaglutide PK Simulator
Indication: Type 2 Diabetes / Obesity
Interactive pharmacokinetic simulator for semaglutide (Ozempic/Wegovy). Explore weekly dosing and steady-state concentrations.
Drug Overview
Clinical Context
- Molecular Target
- GLP-1R
- Drug Class
- GLP-1 RA
- Therapeutic Area
- Metabolic
- Indication
- Type 2 Diabetes / Obesity
- Route of Administration
- SC
Model Information
- Model Type
- PK/PD
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| CL | 0.05 L/h |
| ka | 0.0078 h⁻¹ |
| CL F | 0.035 L/h |
| Tmax | 24-36 h |
| Vc F | 7.38 L |
| t half | ~168 h (1 week) |
| protein binding | >99% (albumin) |
| bioavailability SC | 0.89 |
| bioavailability oral | ~0.01 |
Additional Parameters
| Parameter | Value |
|---|---|
| Vd | 12.5 L |
| IIV CL | 20% CV |
| dose SC | 0.25-2.4 mg weekly |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Semaglutide allows you to explore concentration-time profiles under different dosing scenarios. The underlying PK/PD model characterizes the pharmacokinetics of this glp-1 ra following sc administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Semaglutide PK simulator?
This is a free, interactive pharmacokinetic simulator for Semaglutide used in Type 2 Diabetes / Obesity. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Semaglutide belong to?
Semaglutide is classified as a GLP-1 RA that targets GLP-1R. It is used in the Metabolic therapeutic area.
What route of administration does this model simulate?
This simulator models SC administration of Semaglutide. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PK/PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the half-life of Semaglutide?
Based on the published model parameters, the elimination half-life of Semaglutide is approximately ~168 h (1 week). Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.
What is the clearance of Semaglutide?
The clearance (CL) of Semaglutide is approximately 0.05 L/h. Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.
Explore Other Semaglutide Formulations
Semaglutide is available in multiple formulations with different routes of administration. Compare pharmacokinetic profiles across these FDA-approved products:
Ozempic (Semaglutide) PK Simulator
Route: SC
Type 2 diabetes mellitus
Wegovy (Semaglutide) PK Simulator
Route: SC
Chronic weight management
Rybelsus (Oral Semaglutide) PK Simulator
Route: Oral
Type 2 diabetes mellitus
💡 Did you know? Each semaglutide formulation has unique pharmacokinetic characteristics based on route of administration, dosing frequency, and bioavailability.
Related Simulators
Wegovy (Semaglutide) PK Simulator
Chronic weight management
Trulicity (Dulaglutide) PK Simulator
Type 2 diabetes mellitus
Rybelsus (Oral Semaglutide) PK Simulator
Type 2 diabetes mellitus
Ozempic (Semaglutide) PK Simulator
Type 2 diabetes mellitus
Insulin PK Simulator
DKA/Diabetes
Weight-HbA1c-Glucose Model
Obesity/T2DM
Ready to Simulate?
Launch the Semaglutide simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community